181 related articles for article (PubMed ID: 27599145)
1. Imaging oligometastatic cancer before local treatment.
Franklin JM; Sharma RA; Harris AL; Gleeson FV
Lancet Oncol; 2016 Sep; 17(9):e406-14. PubMed ID: 27599145
[TBL] [Abstract][Full Text] [Related]
2. A multinational report of technical factors on stereotactic body radiotherapy for oligometastases.
Redmond KJ; Lo SS; Dagan R; Poon I; Foote MC; Erler D; Lee Y; Lohr F; Biswas T; Ricardi U; Sahgal A
Future Oncol; 2017 May; 13(12):1081-1089. PubMed ID: 28152619
[TBL] [Abstract][Full Text] [Related]
3. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
5. Approach to Oligometastatic Prostate Cancer.
Bernard B; Gershman B; Karnes RJ; Sweeney CJ; Vapiwala N
Am Soc Clin Oncol Educ Book; 2016; 35():119-29. PubMed ID: 27249693
[TBL] [Abstract][Full Text] [Related]
6. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract][Full Text] [Related]
7. A risk-based approach to identifying oligometastatic disease on imaging.
deSouza NM; Tempany CM
Int J Cancer; 2019 Feb; 144(3):422-430. PubMed ID: 30098215
[TBL] [Abstract][Full Text] [Related]
8. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
Joice GA; Rowe SP; Pienta KJ; Gorin MA
Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
[TBL] [Abstract][Full Text] [Related]
9. Imaging modalities in synchronous oligometastatic prostate cancer.
Futterer JJ; Surcel C; van den Bergh R; Borgmann H; Briganti A; Gandaglia G; Kretschmer A; Ost P; Sooriakumaran P; Tilki D; Valerio M; Ploussard G; De Visschere PJL; Tsaur I;
World J Urol; 2019 Dec; 37(12):2573-2583. PubMed ID: 30069582
[TBL] [Abstract][Full Text] [Related]
10. Modeling growth kinetics and statistical distribution of oligometastases.
Withers HR; Lee SP
Semin Radiat Oncol; 2006 Apr; 16(2):111-9. PubMed ID: 16564446
[TBL] [Abstract][Full Text] [Related]
11. Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box.
Fleming CW; Broughman JR; Tendulkar RD
Curr Treat Options Oncol; 2020 Nov; 22(1):2. PubMed ID: 33216272
[TBL] [Abstract][Full Text] [Related]
12. [Oligometastases and oligoprogressions: Concepts and natural history].
Annede P; Chargari C
Cancer Radiother; 2019 Oct; 23(6-7):475-481. PubMed ID: 31447345
[TBL] [Abstract][Full Text] [Related]
13. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
14. Searching for novel multimodal treatments in oligometastatic pancreatic cancer.
Filippini DM; Grassi E; Palloni A; Carloni R; Casadei R; Ricci C; Serra C; Ercolani G; Brandi G; Di Marco M
BMC Cancer; 2020 Mar; 20(1):271. PubMed ID: 32228504
[TBL] [Abstract][Full Text] [Related]
15. Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.
de Maar JS; Sofias AM; Porta Siegel T; Vreeken RJ; Moonen C; Bos C; Deckers R
Theranostics; 2020; 10(4):1884-1909. PubMed ID: 32042343
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Treatment of Oligometastatic Disease: What the Radiologist Needs to Know to Guide Patient Management.
Rowe SP; Hawasli H; Fishman EK; Johnson PT
Acad Radiol; 2016 Mar; 23(3):326-8. PubMed ID: 26781202
[TBL] [Abstract][Full Text] [Related]
17. Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study.
Christ SM; Pohl K; Muehlematter UJ; Heesen P; Kühnis A; Willmann J; Ahmadsei M; Badra EV; Kroeze SGC; Mayinger M; Andratschke N; Huellner M; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):596-602. PubMed ID: 35908582
[TBL] [Abstract][Full Text] [Related]
18. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Kroese TE; van Hillegersberg R; Schoppmann S; Deseyne PRAJ; Nafteux P; Obermannova R; Nordsmark M; Pfeiffer P; Hawkins MA; Smyth E; Markar S; Hanna GB; Cheong E; Chaudry A; Elme A; Adenis A; Piessen G; Gani C; Bruns CJ; Moehler M; Liakakos T; Reynolds J; Morganti A; Rosati R; Castoro C; D'Ugo D; Roviello F; Bencivenga M; de Manzoni G; Jeene P; van Sandick JW; Muijs C; Slingerland M; Nieuwenhuijzen G; Wijnhoven B; Beerepoot LV; Kolodziejczyk P; Polkowski WP; Alsina M; Pera M; Kanonnikoff TF; Nilsson M; Guckenberger M; Monig S; Wagner D; Wyrwicz L; Berbee M; Gockel I; Lordick F; Griffiths EA; Verheij M; van Rossum PSN; van Laarhoven HWM;
Eur J Cancer; 2022 Mar; 164():18-29. PubMed ID: 35134666
[TBL] [Abstract][Full Text] [Related]
19. Oligometastasis: Past, Present, Future.
Gutiontov SI; Pitroda SP; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):530-538. PubMed ID: 32976785
[TBL] [Abstract][Full Text] [Related]
20. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
Milano MT; Katz AW; Zhang H; Huggins CF; Aujla KS; Okunieff P
Radiother Oncol; 2019 Feb; 131():45-51. PubMed ID: 30773186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
